Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom

British Journal of Ophthalmology

Volumn 88, Issue 11, 2004, Pages 1391-1394

  Zhou, Zhiyuan ^a   Althin, R ^a   Sforzolini, B S ^a   Dhawan, R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; LATANOPROST; MIOTIC AGENT; TIMOLOL;

ARTICLE; DATA BASE; DRUG USE; GENERAL PRACTICE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; CHRONIC DISEASE; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MIOTICS; PROSTAGLANDINS F, SYNTHETIC; RISK FACTORS; SYMPATHOMIMETICS; TIMOLOL; TREATMENT FAILURE;

EID: 7044225903     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.037713     Document Type: Article

References (24)

1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
2. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003;121:48-56.
3. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-5.
4. Kass MA, Gordon M, Morley RE, et al. Compliance with topical timolol treatment. Am J Ophthalmol 2987;103:188-93.
5. Dasgupta S, Oates V, Bookhart BK, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002;8(suppl):S255-61.
6. Shaya FT, Mullins CD, Wong W, et al. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002;8(suppl):S271-7.
7. Spooner JJ, Bullano MF, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002;8(suppl):S262-70.
8. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical prostaglandin therapy in the management of glaucoma. Clin Ther 2003;25:1172-85.
9. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003;13(suppl 4):S44-52.
10. Diestelhorst M, Schaefer CP, Beusterien KM, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol 2003;13(Suppl 4):S21-9.
11. Garcia Rodriguez LA, Pérez Gutthann S. Use of the UK Genera Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25.
12. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-78.
13. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Safety 1992;1:347-9.
14. Van Staa T-P, Abenhaim L. The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Safety 1994;3:15-21.
15. Schwartz GF. Measuring persistency with drug therapy in glaucoma management. Am J Manag Care 2002;8(suppl):S237-9.
16. Lawless JE. Statistical models and methods for lifetime data. New York: John Wiley and Sons, 1982.
17. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
18. Alm A, Stjernschantz J, for the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 1995;102:1743-52.
19. Camras CB, for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-47.
20. O'Donoghue EP, and the UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3-month, randomised study. Br J Ophthalmol 2000;84:579-82.
21. Kampik A, Arias-Puente A, O'Brart DPS, et al. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: A randomized observer-masked multicenter study. J Glaucoma 2002;11:90-6.
22. Stewart WC, Day DG, Stewart JA, et al. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2000;16:557-64.
23. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;131:631-5.
24. Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma 1992;1:134-6.